Summary
Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemetic of the antitumour properties of cisplatin.
This is a preview of subscription content, log in via an institution to check access.
References
Bermudez J, Boyle EA, Miner WD, Sanger GJ (1988) The antiemetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 58: 644
Carmichael J, Cantwell B, Edwards C, Harris AL (1988) Phase I and pharmacokinetic study of BRL 43694, a selective 5-HT3 receptor antagonist: effective control of cisplatin-induced emesis (Abstr 1082). Proc Am Assoc Clin Oncol: 279
Gumbrell RJ, Qualmann C, Perren TJ, Forgeson G, Calvert AH, Thompson S, Rapaport WG (1988) An open pilot study of the 5-HT3 antagonist, BRL 43694, an effective antiemetic in refractory highly emetogenic cytotoxic drug-induced emesis (Abstr 1149). Proc Am Assoc Clin Oncol: 296
Harrap KR (1983) Platinum analogues: criteria for selection. In: Muggia FM (ed) Cancer Chemotherapy 1. Martinus Nijhoff, The Hague Boston London, p 171
Morrison SD (1983) In vivo estimation of size of experimental tumours. J Natl Cancer Inst 71: 407
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goddard, P.M., Jones, M., Pollard, L.A. et al. The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice. Cancer Chemother. Pharmacol. 25, 377–379 (1990). https://doi.org/10.1007/BF00686242
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686242